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W H A T I S O H P A T ?
Administration of parenteral antibiotics outside the inpatient
setting, either outpatient or home parenteral therapy
(OHPAT), can produce considerable savings in hospital costs
[1^3], improve patients' quality of life by enabling them to
remain at home or return to work [4], and greatly reduce the
chance of contracting a nosocomial infection [5]. OHPAT has
become possible following the introduction of better catheters
for vascular access and improved infusion devices [6]. Addi-
tionally, the availability of antibiotics that can be administered
by a simple bolus injection, require once-daily dosing and do
not require serum monitoring makes it easier for patients or
their carers to administer treatment at home [6,7].
W H A T I S T H E E V I D E N C E F O R O H P A T A C T I V I T Y
I N T E R N A T I O N A L L Y ( O U T S I D E N O RT H A M E R I C A ) ?
In the USA, OHPAT services, also known as community-
based parenteral anti-infective therapy (CoPAT), have a well-
developed infrastructure and deliver a high-quality service to
a large number of patients [8]. Indeed, OHPAT services now
account for more than a billion US dollars in healthcare
expenses annually [10].OHPATguidelines already exist from
the USA [9] and Canada [11]. Elsewhere, there is evidence of
evolving interest in OHPAT, with reports of successful pro-
grams in Australia, Argentina, Mexico, Israel and Venezuela
[12]. In contrast, in Europe the existing evidence for OHPAT
services is rather sparse and ill-de¢ned except in some areas of
Italy, Austria,The Netherlands and the UK. Only in the UK
do national OHPATguidelines exist [13], but OHPATservices
have yet to be initiated in the majority of healthcare regions of
this country. Furthermore, a recent survey conducted in Eng-
land revealed that, for patients receiving home infusions, anti-
microbial therapy is primarily con¢ned to cystic ¢brosis and
antivirals forHIVinfection [14].
The lackof clear information on EuropeanOHPAT activity
was evident from the outcomes of an interactive question and
answer session held during an OHPAT workshop at the 2nd
European Congress of Chemotherapy (Hamburg, Germany,
12 May 1998). Fifty-¢ve per cent of those attending the work-
shop did not have an OHPATprogram in place, and, of those
who did, only 26% treated more than 100 patients annually,
with orthopedic and skin and soft tissue infections identi¢ed
as key infections amenable to OHPAT.The majority (89%) of
the audience felt that OHPATactivity would increase over the
next 5 years but that the greatest barriers to progress were
funding issues and the lack of systems or guidelines. This was
the stimulus for the formation of a group (now called the
AdHOC group) of key opinion leaders, primarily from Eur-
ope but including Argentina and Brazil, whose remit was as
follows:
1. to ascertain country-speci¢c denominator data and personal
experiences of OHPATactivity
2. to highlight the key strengths and opportunities for
OHPAT
3. to investigate, individually and as a group, the existing bar-
riers to OHPAT, with emphasis on the ¢scal barriers in the
EuropeanUnion (EU)
4. to o¡er solutions on how these barriers may be overcome
5. to provide a position document on behalf of the group, out-
lining the key issues.
W H A T H A S U K E X P E R I E N C E T O L D U S ?
The relative lack of uniform activity in the UKwas recently
highlighted by the ¢ndings of the ¢rst national survey of
OHPATactivity in theUKand theRepublic of Ireland, as pre-
sented at the ¢rst AdHOC meeting by Nathwani and pub-
lished in this issue of Clinical Microbiology and Infection [15]. A
questionnaire was sent to 348 infection specialists. Of the
responses received (n157), only 21% reported having an
OHPATservice in place already, and the majority of specialists
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without such a service (81%) felt that OHPAT was required
in their region.The most frequently reported factors prevent-
ing the development of an OHPAT service included funding
issues (reported by 36% of 124 responders), lack of leadership
(34%), and di¤culties in coordinating hospital and commu-
nity care (30%). Indeed, lack of guidelines was identi¢ed as a
barrier by only 6% of individuals, presumably acknowledging
the existence of the UK guidelines. Similar problems appear
to bewidespread throughout Europe, whereOHPATis largely
driven by a few clinical enthusiasts working without o¤cial
support for the funding, development and implementation of
such programs [16].
Those with existing services in the UK have claimed that
OHPAT is only a reasonable option in small numbers of
patients [17]. However, a feasibility study conducted in Scot-
land showed this is not the case, as 86% of inpatients receiving
intravenous antibiotics were found to be suitable for OHPAT
and the patients also considered this to be a suitable option for
treatment [18].
W H A T I S T H E EV I D EN C E F O R TH E B EN E F IT S O F
O H PA T IN T ER N A T IO N A LL Y ( O U T S ID E N O R T H
A M E R IC A )?
Despite receiving little or no o¤cial support, OHPAT pro-
grams outside of North America have been shown to be clini-
cally e¡ective, safe, cost-e¡ective and associated with
attendant improvements in quality of life [12, >19^28]. Pro-
grams involving teicoplanin, a drug not available in North
America, have provided a signi¢cant component of OHPAT
experience, as recently summarized by Nathwani [29] and
Wilson and Gruneberg [30].
Experience from one of the larger centers clearly reveals a
signi¢cant number of positive outcomeswithOHPAT. In Tay-
side, UK, 101 patients were treated under the OHPATscheme
over a period of 1year [25].The majority (51.5%) had compli-
cated skin or soft tissue infection, 22.8% had osteomyelitis or
septic arthritis, and 3.9% had bacterial endocarditis.The clini-
cal outcome was c`ure/improving' in 94%, with`no change' in
a further 2%, and adverse drug reactions and unscheduled
readmissions occurring in 6% and 7.5% of cases, respectively.
In regard to economic outcome, it was estimated that 1461
hospital bed days had been saved, and the mean increase in
drug acquisition cost per patient was less than »12/day. The
antibiotics used, such as teicoplanin and ceftriaxone, were
more expensive than those recommended in the hospital sepsis
protocol but o¡ered once-daily administration, and were of
proven e¤cacy and safety in the OHPAT setting [24]. Addi-
tionally, 93% of patients said the OHPAT service was prefer-
able to inpatient treatment, 93% of patients' families or carers
were satis¢ed with the service, and 96% of patients said that
the service improved their quality of life [25].
The bene¢ts of OHPAT programs to the patient are
obvious. Recent work suggests, however, that it is important
to evaluate closely patients' perceptions of home and hospital
as sites of treatment for acute illness [31]. If necessary, these
perceptions should be addressed through education, to ade-
quately convey the experience of safety and e¤cacy to the
patient population. Bene¢ts to providers, such as hospitals and
payers (e.g. social security or insurance companies), need to be
carefully delineated against the background of the unique ¢s-
cal/accounting structure of each country within Europe and
worldwide. One accepts that, although the demands and
needs of many countries are similar, there is considerable dis-
harmony related to healthcare and insurance systems. How-
ever, the bene¢ts which can be gained from OHPAT suggest
that a more organized strategy should be developed in Europe
[8].
T H E A D H O C G RO U P
During a workshop held in Paris on 21 and 22 January 2000,
the barriers which limit usage of OHPAT in countries outside
of North America were examined. The aims were as pre-
viouslyoutlined.
To understand the composition of the group, their experi-
ence, the dynamics of OHPAT in each country/region and the
key factors (e.g. economic, educational, logistic) controlling
OHPAT, a questionnaire was sent to all participants (Table1).
An analysis of the responses was presented to the group and
formed the basis of three key areas/questions:
1. Describe the ideal OHPATfor your country.
2. What issues/barriers must be addressed to attain the best
position forOHPAT?
3. How are you going to handle/resolve these barriers, i.e. pro-
vide solutions?
To arrive at a consensus, the technique of meta-planning
was used, as described previously [32]. In brief, a meta-plan
session involves interactive discussion, facilitated by a modera-
tor, structured to encourage the £ow of ideas and information
from the groupwithout undue peer pressure, in order to arrive
at a consensus.The complete generation, grouping and priori-
tization process pertinent to the above key questions is out-
lined in the following sections.
The members of the workshop included infectious disease
and internal medicine specialists, and experts in the ¢elds of
clinical epidemiology, health economics and oncology/hema-
tology (see Appendix). The participants represented 11 Eur-
opean countries and two South American countries.
Although most of the discussions centered on OHPAT, the
majority of issues raised were considered to be applicable to
other forms of non-inpatient parenteral therapies, e.g. cancer
chemotherapy, blood transfusions, and palliative care. Indeed,
early in the discussions, the group recognized the need to learn
ãåäNathwani and Zambrowski AdHOC consensus statement
= 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 464±476
from the experiences gained from other home and outpatient
treatments [33]. The assigned name of the workgroup took
this into account: the Advisory group on Home-based and
Outpatient Care (AdHOC). The outcomes from the ¢rst
workshop are presented in detail here.We hope that this will
lead the debate onOHPAT in Europe andworldwide and pro-
vide a basis for its broader implementation and evaluation.
A D H O C ME M B E RS ' E XP E R IE N C ES O F O H P A T
OHPAT activity: current and future
The experiences of OHPAT reported by the AdHOC mem-
bers provided an indication of its current position within the
European and South American countries represented. Seven
of the 15 physicians already ran an OHPAT service, and a
further four expressed interest in running such a program.
Most participants agreed that OHPATshould begin in hospital
and continue in the community with responsible surveillance.
However, with the development of a more sophisticated com-
munity service, this process can probably be wholly per-
formed in the community, with specialist assessment and
back-up. In Germany, however, treatment continues on an
outpatient basis, as nurses are usually not permitted to admin-
ister intravenous injections.
The level of OHPAT activity in each country varied from
`very little' (Argentina, Belgium, Brazil, Greece,The Nether-
lands) to `widespread' (Turkey, Italy) (Table 2), the latter
re£ecting the widespread use of parenteral (mainly intramus-
cular) antibiotics in Turkey and Italian general practice. This
knowledge was based mostly on personal experience or ad hoc
data, formal survey information being available inThe Neth-
erlands (R. Quak, personal communication), Italy, and the
UK only [14, 34^36]. The expected trend in OHPAT activity
Table 1 Questionnaire completed by AdHOC members
Questionnaire
1. In your own experience, what is OHPAT?
2. What is your interest in OHPAT?
3. Which medical specialities in your country use OHPAT?
4. What is the level of OHPAT activity in your country?
5. What is your information source for the answer to the previous question?
6. Who controls OHPAT activity in your country?
7. What trends do you expect to see in OHPAT in your country during the next 5 years?
8. What are some of the issues that have slowed acceptance/development of OHPAT in your country?
9. What are some of the issues in your country that will cause an increase (or decrease) in OHPAT use during the next 5 years?
10. How should OHPAT be promoted in the future?
11. Any other comments relevant to OHPAT in your country?
Table 2 The level of OHPAT activity in various European and South American countries (AdHOC members' personal experiences)
Country Very little Well accepted but limited to few specialities Used in certain regions only Widespread
Argentina X
Austria X
Belgium X
Brazil X X
Germany X
Greece X
Italy X X
The Netherlands X
Spain X X
Sweden X
Switzerland X
Turkey X
UK X X
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over the next 5 years ranged from a` small increase' (Austria,
Belgium, Greece, Italy, Sweden,The Netherlands,Turkey, the
UK) to a` small decrease' (Italy), with the remainder (Argen-
tina, Brazil, Germany, Spain, Sweden, Switzerland) expecting
a large increase. The small decrease foreseen in Italy is due to
the current limitations on parenteral antibiotic prescription by
general practitioners (GP), imposed recently by the Italian
government.
OHPAT control factors/barriers
Austria, Germany and The Netherlands were the only coun-
tries where reimbursement agencies or insurance companies
were involved with OHPATprograms. In most of the remain-
ing countries, OHPATwas controlled by individuals or indi-
vidual hospitals or hospital departments. The major issues
considered by the group as slowing the acceptance or develop-
ment of OHPAT are listed in Table 3. The group felt that any
increase in OHPAT use over the next 5 years would be in
response to increased hospital costs and the evolution of
healthcare towards the community setting, coupled with
recognition of OHPATas a useful, cost-e¡ective and safe alter-
native to hospital treatment, as demonstrated by existing stu-
dies and experience.
It was generally felt that randomized controlled trials com-
paring non-inpatient therapy with traditional hospital treat-
ment were no longer feasible or ethical. Indeed, when
considering the e¤cacy of antibiotic therapy, there was a gen-
eral opinion that demonstrations of e¤cacy in the inpatient
setting should be considered applicable to the OHPATsetting
also. It was felt that all one needs to prove is the safety, feasibil-
ity and cost-e¡ectiveness of OHPAT, for which there is now
increasing evidence. The over-riding comment from the
majority of respondents was that `if patients demand OHPAT
because it gives them better quality of life, then funding (from
insurance, reimbursement or public bodies) should not be
denied'. In fact, it is likely that patient power plus increasing
empowerment of the public due to the growth and increased
accessibility of information will increase the demand for
OHPAT.The details of this analysis were recently presented at
the 10th European Congress of Clinical Microbiology and
Infectious Diseases, 28^31 May 2000, Stockholm, Sweden
[37].
The following sections condense the key components of
the meta-plan discussion session and provide a keen critique of
how theAdHOCgroup felt about OHPATimplementation.
T H E ID E A L O H P A T S E R V IC E
The features of the ideal OHPAT service identi¢ed by the
AdHOC group, which are listed below, also provide a check-
list of the key barriers to its implementation:
1. Administration by a hospital-based, multidisciplinary
home-care team, led by an OHPATexpert. Although the pre-
scribing physicianwill be ultimately responsible for the deliv-
ery of patient care, it may be preferable that responsibility for
the day-to-day running of the service is taken by a nurse
experienced in non-inpatient parenteral treatment.
2. Service run frommore than one or two centers per country
to givewide availability, with consistency between centers.
3. E¡ective lines of communication established between hos-
pitals and the community.
4. Availability of clear guidelines, including agreed indica-
tions. OHPATgiven clear de¢nitions, as logistic and training
issues will di¡er with the type of parenteral administration
(intravenous/intramuscular/subcutaneous injections).
5. Regular or continuous audit of service by using prede¢ned,
simple, measurable and coherent performance/quality indica-
tors.This should evolve into an international outcome registry
for benchmarking purposes.
6. Rather than being used primarily as a means of reducing
the number of hospital beds, savings should be re-invested,
possibly within other hospital departments.
7. The healthcare system managers, reimbursement agencies
and patients are on board and convinced of the bene¢ts of
OHPAT, as shown by e¤cacy and cost-e¡ectiveness trial data
( e`vidence-based OHPAT'). Changes in healthcare systems
have been made to remove any ¢nancial constraints, or the
process of ¢nancial accountability is clearly de¢ned and easy
to administer.
8. Legal responsibilities are clear for the OHPAT team and
patient, and the service is supported by the regulatory authori-
ties enabling, for example, nurses to administer intravenous
injections in all countries.
Table 3 The issues that have slowed the acceptance or develop-
ment of OHPAT (AdHOC members' personal experiences)
The issues
Financial concerns
Increased cost of hospitalization
Restricted hospital economic policy/lack of ®nancial support
Unfavorable reimbursement systems
Mandatory use of oral antibiotics (Italy)
Increase in cancer and elderly population
Lack of experience/knowledge
Lack of organizational support/government commitment
Legal limitation for nurses
Confused accountability
Unfavorable drug regimens, e.g. too many doses per day
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B A R R IE R S T O O H PA T
In this section, the issues concerning or barriers to attaining
the best position for OHPAT, identi¢ed by the AdHOC
group, are clustered into four major categories, and are the
focus of the remainder of this report:
1. Political and funding issuesöcreating the political will to
make legislative changes. Obtaining the appropriate ¢nancial
support for the creation and maintenance of OHPAT teams,
reimbursement for patient care, payment for equipment sup-
plies and antimicrobial drugs.
2. Lack of international guidelinesöthese must be based on
demonstrations of clinical e¡ectiveness (e¤cacy, safety, and
enhanced quality of life) and cost-e¡ectiveness (illustrated by
the results of pharmacoeconomic studies). Guidelines for
assembling an OHPAT team for patient selection, community
liaison, training of the healthcare team and patients, and mon-
itoring service performance, are also required.
3. Medico-legal issuesöclarifying the legal responsibility for
drug prescribing (allowing community nurses to give intrave-
nous injections), patient outcome, etc., with regulatory back-
up from EUhealthcare authorities.
4. Lack of local awareness of OHPATögenerating awareness
among health professionals, health administrators and
patients, marketing the bene¢ts of OHPAT, and providing the
motivation for local health authorities to change systems.
Political and funding issues
Virtually all countries other than the USA have a nationwide
healthcare system. However, the ability to provide inpatient
parenteral treatment varies according to each individual coun-
try's wealth. In poorer countries without the ¢nances to build
hospitals, the primary form of therapy is often through outpa-
tient clinics when medication is available. Moreover, in areas
of high population density, outpatient treatment is attractive
to hospital administrations unable to supply extra hospital
beds. Most countries, however, have a system of public and
private hospitals and provide intravenous treatment in both
facilities. Where health insurance is available, there may be
incentives for outpatient care, though usually only if the cost
of hospitalization is high. Self-administration may be possible
in countries with greater resources to devote to healthcare,
although, despite saving sta¡ and overhead costs, this requires
investment in vascular access and infusion devices, as well as
well-trained medical personnel to evaluate and monitor
patients'progress.
In the EU member states, health expenditure is approxi-
mately US$1800 per inhabitant per year, equivalent to 7.5%
of the gross domestic product (GDP) [38]. Hospital costs
make up approximately half of total healthcare budgets, and
the high cost of quali¢ed sta¡ takes up a large proportion of
hospital budgets (up to 70%) [38].
The di¡erences between the healthcare systems of indivi-
dual EU countries re£ect di¡erences in culture and history
(Table 4). However, throughout the EU, patient needs and
demands on healthcare systems are similar, as are the techni-
ques of care employed. Therefore, standardization of health-
care funding is, theoretically, possible. Indeed, many EU
policies now emphasize the need for healthcare reform to pro-
vide better care at a reduced cost. This follows the lead of the
USA, where it has been reported that 62% of all healthcare
costs may be unnecessary [9], and policies of managed care
have stimulated a greater emphasis on outpatient therapy [12].
The prevention or reduction of hospital stay underpins much
of this e¤ciency, and it is expected that such policies will have
an increasing in£uence on countries outside of the USA,
including the EU. However, one must recognize a number of
caveats related to the economic value of shortening the dura-
tion of hospital stay, which is constantly put forward as an
appealing argument.These caveats are pertinent to practice or
healthcare in theUK andmany parts of Europe, where there is
no payment by diagnosis-related group (DRG), and hospitals
can increase income by treating more patients. Many hospitals
receive a ¢xed annual budget or block contract for treating a
speci¢ed group of patients, making it more di¤cult to realize
savings through early discharge. In fact, the reality is that sav-
ings attributable to early discharge of patients are usually o¡set
by their replacement with individuals needing more investi-
gation or treatment, thereby increasing the average cost per
day of hospitalization [39,40]. This paradox occurs because
treatment costs are not evenly distributed throughout the
duration of the patient's hospital stay but are likely to be high-
est in the early part of admission, when investigation and
treatment procedures are most intense. The other perceived
bene¢ts of early discharge from hospital are that they will
shorten surgical waiting lists, will not lead to an increase in the
cost of care into the community and will not impose ¢nancial
burdens or inconvenience on the patient, carers or family.
These perceived bene¢ts are often not realized.The advantage
to the community can only be realized if there is also a shift of
resources from the hospital to primary care, or if there is a glo-
bal budget for primary and secondary care or similar ¢nancial
incentive tomove patients out of hospital earlier.
Despite lack of encouragement from European social secur-
ity funds, home-care is already implemented throughout Eur-
ope. However, the separation of budgets for hospitals (within
a public system) and ambulatory care (mainly private) is a sig-
ni¢cant problem. As OHPAT is often regarded as half-way
between both systems, hospital administrators and commu-
nity-based physicians may feel that they do not have the ¢nan-
cial responsibility for it. Additionally, the concept of
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providing better care at a reduced cost in order to increase e¤-
ciency is relatively new among health professionals and health
authorities outside of theUSA. Also, the disadvantages of hos-
pital care have never been evaluated thoroughly. For example,
although hospitals o¡er constantly available, high-quality
care, there is often extreme pressure on hospital beds, and the
increasing incidence of nosocomial infections is problematic
[41^44]. Other factors which need to be assessed include the
psychological and social impact of hospitalization as well as its
economic impact. Indeed, a report of the substantial socio-
economic burden of hospital-acquired infection has recently
been published [45].
Table 4 Healthcare systems of EU countries
Country (Hospital beds
per 1000 inhabitants) Healthcare funding Hospital cost to patient, accessibility
Austria (10/1000) Social security funded by employees and
employers (50%), government
Hospital and ambulatory care free
99% of population covered by
social security
Belgium (10/1000) Health insurance compulsory Hospitalization covered by social security
Private hospitals have contracts with social
security
Tendency to limited hospital access (GP gate-keeper
policy)
Denmark (6/1000) Public health system run by districts and
councils funded by taxes
Free in own region
GP gate-keepers to specialists and hospitals in
non-emergencies
Finland (12.5/1000) Hospital and public health centers funded by
townships (56%), state (36%) and patients (8%)
Hospital patients pay =C21/day
Admission requires agreement of local health center
(gate-keeper)
France (9.5/1000) Hospitals are public, funded by social security Hospital patients pay =C12/day
Admission unrestricted
Home-care service available to hospitalized patients
Germany (10/1000) 1200 health insurance public funds Free
Hospitals funded by global budget Doctor prescription needed for hospital access
Patients with income >=C3000 may choose private
insurance
Greece (5/1000) NHS controls public hospitals Free in public hospital
In private hospitals, reimbursement is limited (05%)
Ireland (6/1000) Public heath system Based on income and taxes
Public, semi-public (Voluntary Public Hospital)
and private hospitals
Free in public hospitals, with small copayment
covered by voluntary health insurance
Italy (7/1000) NHS Public care is free, with a small copayment
Public or private care available Special agreement required for
private hospital treatment
Luxembourg (12/1000) Budgets negotiated with social security system Patients pay a small daily fee
Public (townships) or non-pro®t-making (religious)
hospitals
Access to hospital is unrestricted
The Netherlands (11/1000) Hospitals have a global budget Public care is free
Insurance fund for exceptional risks Those earning >=C27 000 may go private
GP agreement required for hospital admission
Portugal (5/1000) NHS in charge of primary and hospital care Public hospital care is free, access unrestricted
Local health center physicians control home care
Spain (4.5/1000) Social security funded by taxes Public hospitals are free
Most hospitals public Medical prescription needed for admission
Private insurance competes with the public system
Sweden (12/1000) Healthcare mostly public Hospital and ambulatory care is free, with a
=C255/year copayment
Primary care given in district health centers
Global budget based on DRG
UK (5/1000) NHS funded by income tax Free
Hospital trusts negotiate with GPs and local NHS
authorities for services
GPs are fund-holders and gate-keepers to specialists
and Hospitals (this is now abolished: they are in local
collectives responsible for purchasing health care)
GP, general practitioner; NHS, national health service; DRG, diagnosis-related group.
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OHPAT cost±bene®t data
Most of the cost^bene¢t data available on OHPAT have been
generated in North America [3, 46^52], and are less relevant to
European healthcare systems [1]. However, European ¢nan-
cial information is beginning to emerge [24, 53]. For example,
in a retrospective1-year audit of patients with skin and soft tis-
sue infections (SSTI), although most of the patients did not
progress to complications, they occupied hospital beds for a
mean of 5 days, representing 11.4% of the unit's bed occu-
pancy (Table 5) [24]. Even if 75% of all admissions had been
treated with OPHAT, Nathwani et al estimate that 606 bed
days or 10% of the unit's occupied capacity would have been
saved or released for alternative use. Indeed, in Scotland over-
all, it has been estimated that about 4500 patients are admitted
to hospital annually with the primary discharge diagnosis of
cellulitis or erysipelas (D. Nathwani, personal communica-
tion). Their median duration of hospital stay is 4 days, and if
even one day of hospital stay was avoided by OHPAT, an esti-
mated saving of »0.65 million could be made (calculation
based on local mean cost per dayof hospitalization).
Solutions: overcoming OHPAT barriers
Dealing with the reluctance to change
Current methods of hospital funding make administrators
and sta¡ in many countries reluctant to change systems. For
example, in many areas, hospital budgets are dependent on
keeping beds ¢lled. If a hospital is not operating at or above
capacity, outpatient care will reduce bed occupancy further.
Moreover, GPs may feel that the hospital is putting an added
burden on the community for high-technology care.The per-
ceived advantages and disadvantages of primary care have
recently been described [54]. Support from local health autho-
rities will most likely result from the use of cost^bene¢t, e¤-
cacy and safety arguments based on local experience or that
derived from similar healthcare infrastructures. However, it is
clear that:
1. Arguments may be made that the increased cost of using
the generally more expensive parenteral agents favored in the
OPHATsetting is likely to o¡set the potential savings. How-
ever, in reality, this has not proved to be the case [25, 55].
2. The potential impact of outpatient therapy on nurses and
doctors has to be considered. Nurses' and doctors' pay should
not be a¡ected by working in outpatient units as opposed to
other hospital departments. For example, in a fee-for-service
system, physicians' incomes may decrease in an outpatient
unit, as patients may be seen only a few times a week, whereas
in hospital, patients may be seen by several physicians per
day.
3. Hospital rules must be changed to allow free, compassionate
use of drugs and equipment.
4. Funding should be derived from a joint hospital^commu-
nity fund rather than primary care budgets.
In support of OHPAT is the long history of non-inpatient
parenteral treatment for chronic illnesses (such as hemophilia,
sickle-cell anemia, and neutropenia), where cost bene¢ts in
relation to cost of laundry, overheads, and food, etc. have
already been demonstrated [56^62].Therefore, OHPAT is not
a new concept and doctors who have already seen the bene¢ts
to patients and carers should be encouraged to play a part in the
promotion of this service. Additionally, many fund-holders
already recognize the need for change and satisfactory alterna-
tives to address issues of cost containment. Another factor
which may in£uence health authorities'attitudes to OHPAT is
the introduction of budgets based on DRG [63^66], as fund-
ing will be dependent on the disease concerned, rather than
registration of patients in the hospitalward.
Obtaining political support
An international pilot study is required to show that OHPAT
is safe, feasible and cost-e¡ective comparedwith inpatient par-
enteral treatment and has overall cost bene¢ts to institutions in
terms of the proportion of current hospitalized patients who
might be treated in this way (e.g. per 100 000 population).
Prior agreement should be obtained from the local health
authorities involved, and pharmaceutical companies and/or
other organizations should be approached for funding.
The results of the pilot study, and existing evidence or
experience, should be used to lobby European government
and local authorities to provide legislation for OHPAT. The
potential role of OHPAT in programs of integrated primary
and secondary care, which many government policies cur-
rently favor, should be emphasized. For example, in the UK,
governmentWhite Papers issued in 1997 on the Primary Care
Groups [67, 68] provide a useful foundation for the establish-
ment of OHPAT services. These reform papers promote the
evolution of community and ambulatory care.To support the
need for evidence-based practice, the wide diversity of exist-
Table 5 Projected bed days saved if all SSTI admissions were trea-
ted in the outpatient or home setting [23]
Bed days
Available in 1994/95 11 680
Occupied in 1994/95 7 108
Occupied by SSTIs in 1994/95 (mean) 808
Total admissions 1 173
Total admissions with SSTIs 160
Total number of bed days saved if none of the 160 admissions was
admitted to hospital  808/710811.36% of total beds occupied,
re¯ecting 2.5 of the units' beds (22 beds in total).
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ing evidence concerning other non-inpatient parenteral treat-
ments [56^62, 69^74] should be actively collated and dissemi-
nated to regulatory authorities or keydecision-makers.
The development of international guidelines
Models of service delivery need to be adapted according to
local needs and resources [8]. For example, in some areas,
demand for OHPATmay not be high, in which case an exten-
sion of existing services, such as those for parenteral nutrition
or oncology, may be more appropriate than a separate service.
Indeed, in some areas they may be linked to the services pro-
vided for the ambulatory management of deep venous throm-
bosis with low-molecular-weight heparins or intravenous
diuretics for heart failure. Conversely, individual protocols
may be required to address fully the issues speci¢c to hospitals,
ambulatory care units, and home-care. Nevertheless, interna-
tional guidelines are required to serve as a starting point for
the development of local recommendations. These guidelines
would have to be based on:
1. The results of need assessment studies demonstrating that
OHPAT is a viable option.The proportion of patients suitable
for transferral to OHPAT programs should be calculated as
part of a formal European assessment.
2. Large clinical trials demonstrating the e¤cacy, safety and
cost-e¡ectiveness of OHPAT. These studies should be an
extension of e¤cacy and safety trials conducted in hospitals,
and should also examine the impact on patient and carer qual-
ity of life.
3.The demonstration of reliability, i.e. ease of procedures, e¤-
ciencyof service, consistency between centers, etc.
The component parts making up a g`eneric' protocol for
OHPAT are shown in Figure 1. Key to its development is the
input of a European or international panel, composed of phy-
sicians, microbiologists, nurses, politicians, health economists,
health administrators, and patients. These guidelines should
then be adapted for local use by a multidisciplinary team. It is
crucial for the local success of any program that generic or
national guidelines are used mainly as a basis for steering local
practice so as to encourage ownership. Precise details of the
content of an OHPAT protocol have been published pre-
viously in the North American and UK guidelines [9, 11, 13],
and so are not discussed here.
The organization of a home-care team
The organization of a home-care team should be robust and
readily reproducible between centers (the proposed infrastruc-
ture is illustrated in Figure 2). In particular, the assessment and
discharge planning process should include both hospital and
community-based sta¡ [8]. In many centers, hospital doctors
not familiar with or without expertise in non-inpatient treat-
ment routinely make decisions regarding hospital admissions/
discharge.With the introduction of an OHPAT service, how-
ever, the OHPAT home-care team leader (ideally an infection
specialist) should liaise with attending teams to advise them
on the suitability of their patient forOHPAT.This relationship
should be purely voluntary on the part of the attending clini-
cian and the patient. The OHPAT team leader should ideally
Figure 1 Flowchart for the production of international OHPAT guidelines.
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work with a nurse practitioner, who would undertake the
pivotal role of coordinating the daily process of care.The team
leader, in conjunctionwith the OHPATnurse, would have the
responsibility of coordinating and monitoring the discharge
plan, obtaining input from other members of the team, the
patient and the patient's carer. Input from the team pharmacist
is of great importance, particularly in the development of an
`OHPAT formulary', subject to in£uence by the hospital's
drugs and therapeutics committee. In the fullness of time, this
is likely to evolve into a community or ambulatory care for-
mulary. Procedures must be put in place to enable a rapid £ow
of information to and from team members. Additionally, a
24 -h, on-call system should be instigated to ensure that
patients and clinical sta¡ can receive advice or emergency help
at any time.
The measurement of clinical outcomes is necessary to assess
the e¡ectiveness of any new service, and requires the establish-
ment of clear criteria when the service is being initiated. To
allow the combination of data from several centers, standard
criteria are neededwhich are simple, measurable and clinically
applicable. Integrated care pathways have been suggested as a
potential means of documenting and evaluatingOHPAT para-
meters such as the service's e¡ectiveness, acceptability, and e¤-
ciency [13].These facilitate the introduction of guidelines into
clinical practice, improve multidisciplinary communication
and care planning, measure practice quality standards, increase
consistency, improve communication between the clinician
and patient, and identify areas for research and development
[75]. This methodology has been piloted successfully in an
OHPATstudyconducted inTayside, UK [25].
Medico-legal issues
Clearly de¢ned areas of responsibility must be developed to
de¢ne the roles of all healthcare workers, issues relating to
drugs and equipment, patients'consent to treatment, and treat-
ment outcome. The extent of training and experience of all
members of the hospital-based home-care team, GPs and
Figure 2 Flowchart for the organization of a home-care team.
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community nurses should be recorded for auditing purposes
and the monitoring of e¤cacy and cost-e¡ectiveness. Addi-
tionally, where necessary, training of patients and/or their
carers should be documented.
For the service to work e¤ciently, the legal right for nurses
to administer intravenous injections must be obtained in all
countries. This should be supported by a certi¢cation system
for OHPAT nurses. Certi¢cates would be awarded following
participation in training programs and the accumulation of
training c`redit points' indicating competency to administer
intravenous treatment.
Creating local awareness of OHPAT
The process of creating local awareness of OHPAT should be
driven by an opinion leader, such as an infectious disease spe-
cialist or oncologist. The major `target groups' for publicizing
its bene¢ts include:
1. hospital and community medical sta¡ (doctors, nurses,
pharmacists)
2. local healthcare administrators
3. the general public.
Acceptability within hospitals and community-based cen-
ters should be generated by regular sta¡ meetings led by an
opinion leader, where the exchange of ideas is encouraged.
Patient and public opinion, particularly in relation to quality
of life bene¢ts and safety (including the lowered risk of noso-
comial infections) has an increasing in£uence on ¢nancial and
political decision-makers.
The strategy for publicizing the bene¢ts of OHPATshould
include submission of abstracts to international congresses,
and publication of research papers, including surveillance data
reports, and d`iscussion/consensus papers' in respected journals
and on the internet. In regard to the latter medium, the devel-
opment of OHPATwebsites will facilitate discussion consid-
erably. An example of such a site can be found at http://
www.ohpat.org.uk (password: qwas).
The implementation process should be supported by:
1. International medical societies, such as the World Health
Organization (WHO) and the European Society for Clinical
Microbiology and Infectious Diseases (ESCMID). Close
a¤liation of AdHOC with an international body whose
membership is not restricted to Europe will encourage appli-
cation of guidelines in a broad range of countries with health-
care structures similar to European models, and increase the
credibility of any publications.
2. Home-care organizations.
3. Pharmaceutical societies and companies, including drug
and equipment providers.
4. Political healthcare groups.
5. Patient organizations.
C O N C L U SI O N
The aim of the ¢rst meeting of (AdHOC) was to identify the
key limiting factors preventing the development and imple-
mentation of non-inpatient parenteral therapies, focusing on
OHPAT in particular. This form of therapy has been success-
fully implemented in countries with adequate resources for
healthcare, primarily the USA, but also has potential bene¢ts
elsewhere [12].
Financial and political issues are the most common barriers
to the implementation of non-inpatient treatment services.
Current healthcare systems frequentlydo not have the £exibil-
ity to fund programs of integrated primary and secondary
care. However, policies in many countries now emphasize the
need for healthcare reform to provide better care at a reduced
cost. Additionally, the concept of managed care, which con-
tinues to expand outpatient and home therapy in the USA, is
likely to bring changes to other countries as well [12].
Convincing the decision-makers of the bene¢ts of
OHPATwill require data showing that it is cost-e¡ective, safe
and e¤cacious ( e`vidence-based OHPAT'). In the short to
medium term, this will require:
1. A needs assessment for OHPAT. A broad survey should be
performed, basing the protocol on those used for local surveys
carried out inTheNetherlands, Italy, and theUK.
2. Demonstration of economic bene¢t. A pharmacoeconomic
study is required, with a protocol applicable to a large number
of countries, and involving one or two infections amenable to
OHPAT.
3. Collation of relevant clinical e¡ectiveness and outcome
information on OHPAT and other non-inpatient parenteral
treatments. This must be used to in£uence political, patient
and public healthcare groups, and will most likely require the
sponsorship of pharmaceutical drug and equipment manufac-
turers, large scienti¢c organizations, home-care organizations,
and/or other pharmaceutical companies and societies.
The precise role of AdHOC in facilitating this process is
yet to be decided. In the immediate future, however, AdHOC
aims to form close a¤liations with international medical
societies in order to broaden and increase the impact of any
guidelines produced. AdHOC will also actively seek funding
for the trials necessary to promote OHPAT as a means of
addressing the need for cost containment and reducing rates of
nosocomial infections, while improving patients' and carers'
quality of life. In the longer term, it is likely that other non-
inpatient parenteral treatments will be supported byAdHOC
in a similar way.
In conclusion, the bene¢ts which can be gained from
OHPAT suggest that a more organized strategy should be
developed in Europe. This document aims to serve as a ¢rst
step in the development of international guidelines which can
then be adapted easily for local use. A focused and interna-
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tional approach to the collation of data should assist in ensur-
ing that the changes in funding, reimbursement and legisla-
tion, required to support OHPAT and other non-inpatient
parenteral treatments, are made.
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